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Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by immune mediated biliary damage and frequent
appearance of autoantibodies against mitochondrial enzymes. There is almost no useful animal model that is globally recognized
and routinely used, however, several unique animal models manifested the characteristic clinical and pathological features of
human PBC within the last 5 years. Herein, we compare the pathological features of previously reported and newly introduced
novel animal models of PBC. Knowledge and understanding of the strengths and the limitations of each animal model have led
to the development of promising therapies and novel tools to characterize these clinical conditions. Moreover, suitability of the
model for the intended purpose should be confirmed by further research and analysis.
1. Introduction
Primary biliary cirrhosis (PBC) is an autoimmune disease
of the liver that often develops in middle-aged women.
Antimitochondrial antibodies (AMAs) appears in the serum
of almost all cases of PBC while the occurrence of AMA is
rare in other diseases. The major autoantigens recognized
by AMA are identified as the E2 subunits of pyruvate
dehydrogenase (PDC-E2), branched-chain 2-oxo acid dehy-
drogenase (BCOADC-E2), and 2-oxo-glutarate dehydroge-
nase (OGDC-E2) [1–3]. AMA or anti-PDC-E2 antibody is
therefore an extremely useful diagnostic marker of PBC.
Pathological destruction of interlobular bile ducts in the
liver associated with lymphocytes and plasma cells is known
as chronic nonsuppurative destructive cholangitis (CNSDC)
and is considered the primary lesion of PBC, and eventually
the interlobular bile ducts are destroyed, cholestasis occurs,
bile ductules proliferate, and fibrosis develops as the disease
advances. In some cases, an epithelioid granuloma is devel-
oped in the portal tract accompanied by varying degrees of
eosinophilic infiltration [4–12]. PBC is considered a proto-
type of autoimmune diseases of the liver; it is responsible for
both humoral (appearance of AMA/anti-PDC-E2 antibody)
and cellular immunity (CNSDC, granuloma formation, etc.).
An animal model of PBC that reflects both humoral and
cellular immunological features is useful in elucidating the
underlying pathophysiology of the disease or establishing an
eﬀective treatment. In addition, the characteristic pathophys-
iological findings of the disease such as the presence of related
cytokines and chemokines, nature of inflammatory cells,
extent of bile duct destruction, and granuloma formation
are considered important aspects of the animal model
of PBC. Moreover, ease of handling, the frequency with
which relevant pathophysiology develops, and flexibility are
important elements. The development of an animal model
of PBC has been attempted at many research institutes over
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a number of years; moreover, some animal models that
show pathophysiological symptoms similar to those of PBC
have been reported [12–22]. Currently, however, there is
almost no useful animal model that is globally accepted
and routinely used. Within the last 5 years, there have been
also reports of several murine models that manifest the
characteristic clinical features of human PBC. In this review,
we compare the pathological features of previously reported
animal models and a newly introduced novel animal model
of PBC.
2. Previously Reported PBC Animal Models of
PBC (up to 2005) (Table 2)
Attempts have been made to develop an animal model of
PBC in many institutions. In 1989, Krams et al. immunized
mice of various strains such as AKR/J, C3 H/J, and CBA/HeJ
with recombinant polypeptides of dihydrolipoamide acetyl-
transferase, which is a constituent of the pyruvate dehy-
drogenase complex (PDC), and verified that an anti-PDC
antibody appeared in each mouse strain although antibody
titer levels varied among the strains. However, there were
no signs of inflammation or bile duct lesions in the portal
tract [13]. Krams et al. transferred lymphocytes from the
peripheral blood of a PBC patient into severe combined
immunodeficient (SCID)mice, which resulted in the appear-
ance of AMA and anti-PDC-E2 antibodies, as well as marked
lymphocytic infiltration around the interlobular bile ducts
with slight morphological damage to the portal tract. This
was a successful animal model from the perspective of
humoral and cellular immunity [14]. However, this model
was diﬃcult to reproduce and was only moderately flexible;
furthermore, it was not suitable for the analysis of patholog-
ical lesions. Masanaga et al. in 1998 used PDC to immunize
A/J mice that were neonatally thymectomized, and they
succeeded in inducing pathognomonic cholangitis/biliary
damage. Although the bile duct lesion in this model was
similar to that of human PBC, the appearance of AMA was
not clearly described, and the removal of the thymus in
the neonatal period posed as a technical diﬃculty [15, 16].
Tsuneyama et al. [17] and Ohba et al. [18] reported the
presence of AMA in the serum of MRL/lpr mice, a model
of autoimmune disease in which vasculitis, glomerular
nephritis, arthritis, inflammation of the salivary glands, and
interstitial pneumonia develop spontaneously in the same
individual. Because inflammatory cell infiltrates and biliary
damage in the portal tract similar to that seen in PBC also
appeared in the liver of MRL/lpr mice, it was assumed that
this mouse may serve as a model of PBC. However, the fact
that only about 50% mice showed PBC-like features was
a serious problem. The most widespread animal model of
PBC is considered to be a graft versus host disease (GVHD)
model [19–22]. Initiating the development of GVHD by
transferring splenic immune cells from a donor mouse into
a host mouse with major histocompatibility complex class-
II antigens diﬀerent from those of the donor leads to the
appearance of an underlying autoimmune-like mechanism,
such as hypergammaglobulinemia and the production of
AMA. Furthermore, the initial pathological changes of PBC
with similar associated findings appear in the liver. There
have been several pathological analyses using the advantages
of this animal model of PBC [19–22]. However, this model is
now seldom used, due to its complexity and/or low flexibility.
3. Novel Animal Models of
PBC (Since 2006) (Tables 3 and 4)
Several novel animal models of PBC have been reported
since 2006. These can be roughly classified into spontaneous
models, which employ genetic modifications seen in animals,
and induced models immunized with xenobiotics whose
structures are similar to that of PDC-E2.
Each of these new models shows autoantibodies charac-
teristic of PBC, as well as the appearance of hepatic and bile
duct lesions. Their profile also resembles that of PBC with
respect to infiltrating inflammatory cells and the appearance
of serum inflammatory cytokines. Furthermore, it is easy
to establish experimental systems with these models, such
as immune cell transfer and mating with other transgenic
(Tg) and knockout (KO) mice. Therefore, they fulfill many
of the requirements for a PBC animal model, as listed in
Table 1, and are currently applied in various investigations of
PBC worldwide. Although these animal models are currently
considered among the most useful models of PBC, their
pathophysiology needs further investigation because some
models may show complications that are unusual in PBC,
such as peritonitis or inflammatory bowel disease. The
pathological features of each of these animal models are
outlined below.
4. Spontaneous Models
4.1. The NOD.c3c4 Mouse. Nonobese diabetic (NOD) mice
are a well-knownmodel exhibiting susceptibility to the spon-
taneous development of autoimmune insulin-dependent
diabetes mellitus (IDDM) [41]. Genetic loci associated with
susceptibility to IDDM, as well as several insulin-dependent
diabetes (Idd) loci and candidate genes, have been defined
through the development of congenic mouse strains [42–
44]. NOD mice are also prone to the development of other
autoimmune syndromes in addition to IDDM [45]. In the
NODc3c4 mouse model, the diabetes susceptibility genes
on chromosomes 3 and 4 of the NOD mouse are replaced
with the diabetes resistance genes of B6 and B10 mice,
respectively. Although this helps in controlling the onset of
diabetes in this mouse, autoimmune cholangitis and biliary
dilatation similar to that seen in Caroli’s disease appear.
Serologically, AMA appears in 50–60% and antinuclear
autoantibodies (ANA) in 80–90% of the animals. Immuno-
histochemical analysis demonstrated that the aﬀected parts
of the biliary epithelium are infiltrated with CD3+, CD4+,
and CD8+ T cells. Furthermore, treatment of NOD.c3c4
mice with monoclonal antibody to CD3 protects them from
autoimmune biliary disease. NOD.c3c4-scid mice develop
the disease after adoptive transfer of splenocytes or CD4+ T
cells, demonstrating a central role of T cells in pathogenesis
of the disease in this model [23, 24]. Recently, aggre-
gated lymphocytes surrounding the bile ducts resembling
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Table 1: Requirements for the ideal animal model of PBC.
(i) Specific liver pathology (cellular immunity)
(1) Destruction of interlobular bile duct
(2) T-cell aggregation around the damaged bile ducts
(3) Epithelioid granuloma formation
(4) Fibrosis/cirrhosis
(ii) Specific autoantibodies (humoral immunity)
(1) Antimitochondrial autoantibodies (AMAs)
(2) Anti-PDC-E2 antibodies, anti-BCOADC-E2 antibodies,
and anti-OGDC-E2 antibodies
(3) Antinuclear antibodies (ANAs)
(iii) Other immunological characters
(1) Increase in inflammatory cytokines
(2) Decrease in functional regulatory T cells
(3) Increase in natural killer T (NKT) cells
(iv) General versatility
(1) High reproducibility and disease frequency
(2) Simplicity of model production
(3) Long-term maintenance of disease
(4) Long lifespan without severe complicating disorders
the aggregations seen in Sjogren’s syndrome, were observed
in the salivary glands of this mouse [25]. Because Sjogren’s
syndrome is often seen as a complication in PBC patients,
the pattern of inflammation seen in NOD.c3c4 mice has
many similarities to those seen in PBC. However, the cyst-
like dilatation of the aﬀected bile duct that is characteristic
of these mice is not seen in PBC patients at all. When
the dilatation becomes marked, the biliary epithelium of
NOD.c3c4 mice frequently exfoliates, and the exfoliated cells
together with infiltrated histiocytes fill the lumen. If such
dilatation becomes significant, neutrophil infiltrationmay be
also observed resulting in a variable clinical picture such as
cholangitis. Therefore, further pathological evaluation of this
phenomenon is mandatory.
4.2. The Dominant Negative TGF-β Receptor II Mouse.
Dominant negative TGF-β receptor II (dnTGF-βRII) mice
overexpress the dominant negative form of TGF-β receptor
type II under the control of the CD4 promoter [46].
Deficiency of TGF-β signaling results in various pleiotropic
immunological abnormalities including colitis and relatively
short lifespan [47–49]. dnTGF-βRII mice exhibit major
serological and histological characteristics of human PBC,
suggesting that the TGF-β signaling pathway is important
in the pathogenesis of PBC. Serologically, AMA appears in
100% of these mice. The corresponding antigens include
PDC-E2, BCOADC-E2, and OGDC-E2; these are the main
autoantigens recognized by AMAs of PBC. Furthermore,
hepatic lesions characteristic of PBC, such as lymphocytic
infiltration, interlobular bile duct destruction, and granu-
loma formation in the portal tract, appear at high frequency.
Various infiltrating cells are found in the portal tracts,
including B cells, plasmacytoid dendritic cells, NK cells,
and macrophages, in addition to CD4+ and CD8+ T cells.
Table 2: Representative PBC animal models reported up to 2005.
(1) PDC-immunized mice [13]
(2) Neonatally thymectomized mice with PDC immunization
[15, 16]
(3) MRL/lpr mice [17, 18]
(4) GVHD model [19–22]
Table 3: Novel PBC animal models reported since 2006.
Spontaneous models
(1) NOD.c3c4 mice [23–25]
(2) Dominant negative TGF-β receptor II mice [26–31]
(3) IL-2 receptor α−/− mice [32, 33]
(4) Scurfy mice [34]
(5) Ae2a,b−/− mice [35]
Xenobiotic-immunized induced model
(1) 6-Bromohexanoate-immunized guinea pigs [36]
(2) 2-Octynoic acid-immunized mice [37–40]
A particular characteristic is the increased ratio of CD8+
T cells to CD3+ T cells. This mouse strain presents mild
inflammatory bowel disease and crypt abscesses similar to
those of ulcerative colitis. Increased levels of inflammatory
cytokines such as TNF-α, IFN-γ, IL-12p40, and IL-6 are also
detected in the serum of these mice [26].
The dnTGF-βRII mouse is a spontaneous PBC model in
which pathophysiological variations are minimum among
individuals; furthermore, humoral and cellular immune
responses appear to be reproducible and at high frequency. It
has given rise to many models that are used for pathophysio-
logical analysis. Yang et al. produced a model by transferring
various fractions of splenocytes of dnTGF-βRII mice into
Rag-1−/− mice. Their study revealed that PBC-like hepatic
lesions were produced after the transfer of total splenic
lymphocytes and that more severe hepatic lesions occurred
after splenic CD8+ T-cell transfer. On the other hand, PBC-
like hepatic lesions did not appear, however the colitis
worsened after splenic CD4+ T-cell transfer. Currently, the
CD8+ T-cell transfer model shows maximum similarities to
PBC, such as severe inflammatory cell infiltration, bile duct
destruction, and granuloma formation in the portal tract
[27]. A derived PBC model, produced by crossing dnTGF-
βRII mice with a variety of genetically modified mice, is also
used for pathological analysis.Moritoki et al. crossed dnTGF-
βRII mice with mu-mutant mice (Igμ−/−) to produce a B-
cell-deficient model in order to study the role of B cells in
the pathogenesis of PBC [28]. Chuang et al. studied NKT-cell
commitment in a model produced by crossing dnTGF-βRII
mice with CD1d−/− or CD1d+/− mice [29]. To investigate
the roles of various cytokines, Yoshida et al. and Zhang et al.
produced animal models by crossing dnTGF-βRII mice with
IL12p40 KO and IFN-γ KO mice and by crossing dnTGF-
βRII mice with IL-6 KO mice, respectively [30, 31]. Each
of these derived models makes a considerable contribution
to the pathological analysis of PBC. Interestingly, the grade
of hepatic lesions in animal models produced by crossing
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does not vary greatly among individuals; moreover, it is easy
to assign scores to diﬀerent degrees of pathology for the
purpose of evaluation. The dnTGF-βRIImousemodel is now
used in various analyses throughout the world, and it may
be regarded as the most useful PBC animal model available
at present. However, it is not totally satisfactory as a PBC
model because the pathophysiological grade is not severe;
furthermore, events that occur in the advanced stage of PBC,
such as loss of the bile duct, cholestasis, and fibrosis, are
rarely seen. Therefore, the pathophysiological model based
on this mouse needs to be further developed.
4.3. The IL-2 Receptor α−/− Mouse. IL-2 is critical for the
development and peripheral expansion of CD4+ CD25+
Tregs that promote self-tolerance by in vivo suppression of
T-cell responses [50, 51]. In IL-2 receptor α−/− (IL-2R-α−/−)
mice, the IL-2 signal, which is important in controlling the
fate of mature T cells, is intercepted; these mice develop
an inflammatory bowel disease and a lymphoproliferative
autoimmune disease. Also, 25–50% mice develop severe
hemolytic anemia at 8–20 weeks of age. It was reported that
children with a genetic deficiency of IL-2R-α developed clin-
ical manifestations similar to those of PBC [52]. Anti-PDC-
E2 antibody is present in the serum of all IL-2R-α−/− mice,
and ANA is also present in the serum of 80% of these mice.
There is profound lymphocytic infiltration in the portal tract
and the interlobular bile duct is also damaged. CD8+ T cells
are predominant among the infiltrating lymphocytes, and
CD4+ T and B cells are also present in increased numbers. In
addition, granulomas are formed, though in small numbers.
Increased levels of inflammatory cytokines such as TNF-α,
IFN-γ, IL-12p40, and IL-6 are present in the serum. The
extent of inflammatory bowel disease is relatively severe and
frequently associated with formation of crypt abscesses [32].
Using a derivedmodel produced by crossing IL-2R-α−/− mice
with CD4 KO and CD8 KO mice, Hsu et al. showed that
CD8+ T cells participate in the pathogenesis of PBC [33].
The hepatic lesions of IL-2R-α−/− mice are similar to those
of PBC, though the complication of severe hemolytic anemia
or colitis has not been evaluated. Moreover, the reduced
lifespan of these mice makes it diﬃcult to use them in
various experiments, such as those involving mating; this is
considered a limitation of this model.
4.4. The Scurfy Mouse. The Scurfy mouse is a mouse with
loss of functional regulatory T cells caused by the forkhead
boxp3 (Foxp3) gene mutation. AMAs are present in all Scurfy
mice at 3-4 weeks of age, and the portal tract showsmoderate
to marked lymphocytic infiltration and development of a
severe interlobular bile duct lesion similar to PBC with high
levels of cytokines such as TNF-α, IFN-γ, IL-6, IL-12, and IL-
23 present in the serum and liver. However, Scurfy mice have
an extremely short lifespan of about 4 weeks. This is a serious
drawback with regard to its use in experiments [34].
4.5. Ae2a,b−/− Mice. The anion exchanger (Ae)2a,b-deficient
mouse model was constructed by Salas et al. in Spain,
based on a clinical investigation showing that Ae2 gene
expression was reduced in liver biopsy specimens and blood
lymphocytes from patients with PBC [35]. Ae2a,b−/− mice
exhibit enhanced production of IL-12p70 and IFN-γ, an
expanded CD8+ T cell population, and a reduced number
of Treg cells. Serum analysis by immunoblotting showed that
9 out of 11 Ae2a,b−/− mice had AMAs. A histological study of
liver sections from 11 Ae2a,b−/− mice revealed mild to severe
portal inflammation in 10 animals. Although the mechanism
leading to the deficiency of AE2 in the liver and blood
mononuclear cells in human PBC is unclear, observations
of Ae2a,b−/− mice indicate a relationship between biliary
epithelial dysfunction and the pathogenesis of PBC.
5. Immunity Induced by Xenobiotics in Mice
Not only genetic factors but also various environmental fac-
tors, such as bacterial infection and exposure to xenobiotics,
are strongly implicated in the onset and development of PBC.
Most importantly, prolonged exposure over an extended
period of time to various xenobiotics with a structure
similar to that of the inner lipoyl domain of PDC-E2 has
attracted attention as a trigger for the development of PBC.
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It has been revealed that two types of xenobiotics induce
a pathophysiology that is very similar to that of PBC.
5.1. Guinea Pigs Immunized with 6-Bromohexanoate. 6-
Bromohexanoate (6-BH) coupled with bovine serum albu-
min (BSA) has a structure similar to that of the inner lipoyl
domain of PDC-E2 [53]. Increased levels of anti-PDC-E2
antibody, anti-BCOADC-E2 antibody, and anti-OGDC-E2
antibody appear in the serum of guinea pigs when they
are immunized with BSA-coupled 6-BH. In addition, slight
to moderate lymphocytic infiltration, interlobular bile duct
irregularity, and granuloma formation in the portal tract
are seen in the liver at an advanced age. Many vacuole-like
lipid droplets are seen in the granulomas, and there are also
aggregations of macrophages that phagocytoze lipids. Since
these vacuolar changes are also seen in control animals to
a slight extent, they may be related to immune reactions to
foreign substances in the oil emulsion. The limitation of this
animal model is the diﬃculty of use in some experiments
because the extent of hepatic lesions is slight and lesions are
slow in development, not appearing until 18 months after
immunization [36].
5.2. Mice Immunized with 2-Octynoic Acid. 2-Octynoic acid
(2-OA) is a xenobiotic widely used as a food additive and as
a component of certain cosmetic products. 2-OA coupled to
BSA has a structure similar to that of the inner lipoyl domain
of PDC-E2 [54]. Wakabayashi et al. immunized C57BL/6
mice with BSA-coupled 2-OA and detected AMA and anti-
PDC-E2 antibodies as well as increased serum levels of TNF-
α and IFN-γ. Marked inflammatory cell infiltration and bile
duct lesions in the portal tract frequently appeared, which
were mainly associated with CD8+ T cells [37]. Using the
same methods, Wakabayashi et al. also succeeded in pro-
ducing a PBC-like lesion in another mouse strain (nonobese
diabetic (NOD) congenic strain 1101) [38]. This model
is innovative because it induces PBC-like pathophysiology
by administration of xenobiotics that may be related to
the cause of PBC. As the reproducibility of this model
is comparatively high and flexibility is also high, various
pathophysiological analyses of this model are in progress in
diﬀerent countries’ institutions [39, 40]. At present, however,
the hepatic and bile duct lesions show many diﬀerences
from those of PBC, and further evaluation of the model
is needed. In the original immunization procedure used
by Wakabayashi et al., BSA-coupled 2-OA was introduced
into the abdominal cavity using complete Freund’s adjuvant
(M. tuberculosis in adjuvant oil), following which BSA-
coupled 2-OA using incomplete Freund’s adjuvant (adjuvant
oil only) was administered every 2 weeks as a booster
immunization. This model always developed peritonitis of
various grades as an adverse eﬀect. A preliminary experiment
is necessary in order to check the extent to which peritonitis
influences the development of pathological changes in the
liver, particularly in that portion which is histologically
evaluated. Moreover, a granuloma often appears in the portal
tract or the hepatic parenchyma; this could be attributed
to the complete Freund’s adjuvant administered at the time
of immunization. However, methods of immunization have
improved; as a result, various modifications designed to
induce more serious pathophysiology can be tested. Reports
of studies using this model are eagerly awaited.
6. Conclusion
The pathophysiology of PBC involves both humoral and cell-
mediated immunity, and it can be considered the prototype
of autoimmune diseases of the liver. The production of a
practical animal model of PBC has been a challenge for
researchers interested in PBC and autoimmune diseases for
many years. Although animal models based on a variety of
mechanisms have been reported from many laboratories, the
ideal animal model has still not been available. Recently,
several PBC animal models based on diﬀerent mechanisms
were reported. While these newer animal models show the
characteristic findings of PBC unlike earlier models, they
still show diﬀerent features from those of human PBC.
Understanding the strengths and limitations of each animal
model is required in order to match the model to the
intended purpose; moreover, suitability of the model for the
intended purpose should be confirmed by further research
and analysis.
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